Ocular Therapeutix Reports Q3 2026 Financial Results and AXPAXLI Regulatory Update
Ocular Therapeutix (OCUL) reported third-quarter 2026 net revenue of $12.9 million, a decrease from $14.5 million in the prior year, primarily due to lower DEXTENZA sales. The company recorded a net loss of $94.8 million ($0.42 per share), driven by increased research and development spending totaling $74.8 million as clinical trials for HELIOS-3 and SOL-X accelerate. Despite the widening net loss, the company maintains a strong liquidity position with $530.6 million in cash and cash equivalents, providing a funding runway into 2028. Management confirmed they are on track to submit a New Drug Application (NDA) for AXPAXLI in wet age-related macular degeneration via the 505(b)(2) regulatory pathway in Q4 2026, which may expedite FDA review.
Tickers: $OCUL
Topics: clinical trials earnings report net loss revenue decline